Ebola virus vaccine trials: the ethical mandate for a therapeutic safety net
نویسندگان
چکیده
1Center for Computational Biology and Bioinformatics, The University of Texas at Austin, Austin, TX 78712, USA; 2Department of Biology and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA; 3Department of Biology and Institute of Infectious Disease Research, McMaster University, Hamilton, ON, Canada; 4Department of Integrative Biology, The University of Texas at Austin, Austin, TX, USA
منابع مشابه
Nubia’s mother: being pregnant in the time of experimental vaccines and therapeutics for Ebola
During the 2014-2016 Ebola epidemic, Médecins Sans Frontières (MSF) treated Ebola-positive pregnant women in its Ebola Treatment Centers (ETCs). For pregnant women with confirmed Ebola virus disease, inclusion in clinical vaccine/drug/therapeutic trials was complicated. Despite their extremely high Ebola-related mortality in previous epidemics (89-93%) and a neonatal mortality of 100%, theoreti...
متن کاملA review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?
Sporadic outbreaks of Ebola virus infection have been documented since the mid-Seventies and viral exposure can lead to lethal haemorrhagic fever with case fatalities as high as 90%. There is now a comprehensive body of data from both ongoing and completed clinical trials assessing various vaccine strategies, which were rapidly advanced through clinical trials in response to the 2013-2016 Ebola...
متن کاملFighting Ebola: A Window for Vaccine Re-evaluation?
The unprecedented magnitude of the 2014/2015 Ebola virus (EBOV) outbreak in West Africa prompted the fast-tracking of experimental live replicating recombinant vaccines into clinical safety trials and field deployment. The epidemic was by far the worst crisis caused by any Filovirus, infecting ten times more individuals than all previous outbreaks combined. The outbreak was eventually brought b...
متن کاملEbola vaccines: keep the clinical trial protocols on the shelf and ready to roll out.
Safe and eff ective vaccines to prevent Ebola infection would be useful in the fi ght against this devastating disease. Depending on their effi cacy, onset of immunity, length of protection, and cost and ease of administration, these vaccines could contain or even prevent an outbreak. During an outbreak, a vaccine could prevent infection of front-line health workers and staff who are engaged in...
متن کاملEbola vaccination: if not now, when?
Ebola virus disease causes severe hemorrhagic fever, with a case-fatality rate of 50% to 90% (1). The ongoing epidemic in West Africa is the largest Ebola outbreak ever recorded and is rapidly crossing borders. The relentless epidemiologic trajectory and geographic dissemination represent a public health crisis that shows no signs of diminishing under current efforts. We believe that the time t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 349 شماره
صفحات -
تاریخ انتشار 2014